Home / GLP-1 appeals / Wegovy

Wegovy (semaglutide) denials

Your insurance denied Wegovy. Here is how to appeal it.

Insurers deny Wegovy far more often than they should, and most patients never push back. Most of these denials are administrative, not a medical disagreement with your prescriber, which makes them winnable. We draft your appeal for free, grounded in your plan's own coverage rules with every citation verified. You review, sign, and file it.

Build my Wegovy appeal, free See the strategy

Free to draft. Every citation checked against your plan's own rules before you file.

Wegovysemaglutide 2.4 mgFDA-approved for weight management

Your deadline

Often 60 to 180 days

From the denial date for your plan's first internal appeal. Your denial notice controls, check it.

Common reasons

Mostly administrative

Missing prior auth, step therapy, BMI or comorbidity not documented, or an anti-obesity exclusion.

What wins

Cite the plan's own rules

Appeals mapped to your plan's published anti-obesity criteria do far better than generic letters.

Why Wegovy gets denied

Wegovy (semaglutide, 2.4 mg weekly injection) received FDA approval in June 2021 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol. The SELECT cardiovascular outcomes trial (2023) added evidence for cardiovascular risk reduction in patients with obesity and established cardiovascular disease. Despite that evidence, insurers deny Wegovy at high rates. The reason is usually a documentation or process mismatch, not a clinical disagreement. The denials cluster into a handful of patterns:

  • Medical necessity criteria not met in documentation. Most plans require explicit documentation of a qualifying BMI (30 or higher, or 27 plus a comorbidity) and prior lifestyle-intervention attempts. If your chart notes did not use the plan's exact threshold language, automated review can flag it as not meeting criteria even when you clearly do.
  • Step therapy, "try a cheaper medication first." Many plans require a documented trial of another weight management medication or a structured lifestyle program before approving Wegovy. If your prior attempts were not documented or were left out of the prior authorization, the plan triggers an automatic step-therapy denial.
  • Prior authorization lapsed or was never filed. Wegovy almost universally requires prior authorization. A lapsed PA at plan renewal, a missed renewal window, or a PA submitted without supporting documentation is one of the most common and most fixable denial types.
  • Blanket anti-obesity medication exclusion. Some employer plans carve out anti-obesity medications entirely. If this applies, the primary appeal angle shifts to the cardiovascular indication: the SELECT trial data supports Wegovy for cardiovascular risk reduction in patients with obesity and established heart disease, which may fall outside an anti-obesity exclusion.
  • Indication mismatch, Ozempic vs. Wegovy. Ozempic (semaglutide 0.5 to 2 mg) is approved for type 2 diabetes; Wegovy (semaglutide 2.4 mg) is approved for weight management. If a claim was submitted with a diabetes code for Wegovy, or vice versa, the denial may be a coding fix, not a clinical battle.
  • Non-preferred formulary tier or quantity limits. Plans may cover Wegovy but place it on a non-preferred tier with higher cost-sharing, or cap the quantity below the therapeutic dose. A formulary exception request, supported by documentation that preferred alternatives are not appropriate, can address this.

How to appeal it

The pattern that wins is precision: make the medical reviewer's job a simple checkbox match against the plan's own criteria. A "not medically necessary" or step-therapy denial for weight management is among the more winnable, because the plan publishes the exact rules it used.

The move: pull the exact coverage policy your plan used for anti-obesity agents, then show, line by line, where your records meet each criterion. Appeals that map to the specific published criteria consistently outperform generic medical-necessity letters, because the reviewer is bound to that policy text.

Read the denial letter carefully

It states a reason code and a deadline. Note both. The reason determines the entire appeal strategy. Note the coverage-policy number the letter cites, you will need that document.

Pull your plan's Wegovy coverage criteria

Every major insurer publishes its medical-necessity criteria for anti-obesity medications on its provider portal or plan-document library. Winning appeals do not argue medicine in the abstract, they show point by point that you meet the criteria the plan itself published.

Gather your supporting documentation

BMI and weight history, comorbidity diagnoses and treatment records, documentation of prior weight management interventions (medications or structured programs), and your prescriber's notes. The goal is paper documentation of every criterion the plan lists.

Write the appeal, matching your facts to the criteria

State your appeal rights under the ACA. Cite Wegovy's FDA approval (June 2021) for the correct indication, and the SELECT trial for cardiovascular data if applicable. Then map each documented fact to the plan's specific published criteria. Every citation must be real and verifiable.

File before the deadline and keep proof

Submit through the channel your plan specifies. Keep proof of filing (certified mail, fax confirmation, or portal timestamp). Calendar both the internal appeal decision deadline and the external review request deadline so you have a backup path if needed.

Sources include your plan's published coverage policy for anti-obesity agents and the Wegovy prescribing information. We cite the specific policy that applies to your plan when we build your appeal.

The magic is visible

Your appeal, built from your plan's own rules. Every citation checked.

We draft from the sources below, then verify each one before you file. On our held-out testing: 0 invented citations, versus about 1 in 4 for raw AI.

Sample appeal, built from real source types

  • Your plan's coverage policyThe specific anti-obesity agents policy that applies to your planVerified
  • FDA labelSemaglutide (Wegovy) prescribing information, indication and dosingVerified
  • Your recordsYour BMI history, weight-related conditions, and prior therapies, cited back accuratelyVerified

No source we can't show you. No citation we haven't checked. See it on your own denial, free.

Let's check your Wegovy denial, free.

Answer a few questions for an honest read on your odds, then your verified draft. No account, no cost.

Check my denial, free

Wegovy denial: common questions

Why did my insurance deny Wegovy?
Most commonly: your documentation did not establish a qualifying BMI or comorbidity in the plan's required terms; the plan has a step-therapy requirement you have not yet satisfied on paper; prior authorization was not filed or lapsed; the plan has a blanket anti-obesity medication exclusion; or an indication mismatch created a coding error. The vast majority are administrative, not medical disagreements with your prescriber.
How long do I have to appeal?
Most commercial plans give you 60 to 180 days from the denial date for an internal appeal. The exact deadline is on your denial letter and it controls. If the internal appeal is denied, you generally have about four months to request independent external review. The clock starts at the denial date.
What if my plan excludes anti-obesity medications entirely?
A blanket exclusion is harder to overturn but not always a dead end. The SELECT trial (2023) showed Wegovy reduces major cardiovascular events in patients with obesity and established cardiovascular disease. If your prescriber supports it, the appeal targets that cardiovascular indication rather than weight management, which may fall outside the exclusion language in your plan. We will tell you honestly whether that path applies.
What does my prescriber need to do?
A strong appeal often includes a letter of medical necessity from your prescriber that addresses each criterion in the plan's coverage policy. We generate a template for your prescriber to review, adapt, and sign, and tell you exactly what documentation (BMI, comorbidities, prior treatments) strengthens the appeal. Any fresh clinical opinion comes from a licensed clinician, not from us.
Is this really free?
Yes. We draft your appeal for free and you file it. No fee, no contingency, nothing taken from coverage you win. AppealIt is not a law firm and does not provide legal or medical advice.

Appeal your Wegovy denial by insurer

Pick your plan for its real deadlines, denial patterns, and the appeal strategy that works with it. Every page grounded in that insurer's own rules.

UnitedHealthcare Anthem BCBS Aetna / CVS Health Cigna Humana Kaiser Permanente Centene / Ambetter Molina Healthcare BCBS (HCSC) Florida Blue Highmark Independence BC UPMC Health Plan Oscar Health Medicaid

More on Wegovy denials

Was it a prior auth, or a specific denial reason? Start with the page that matches your letter.

Wegovy prior authorization "Not medically necessary" Step therapy Formulary exclusion Quantity limit Missing documentation

Other GLP-1 appeals: Zepbound · Ozempic · Mounjaro · All GLP-1 denials